Rare Cancers: Special Considerations for Complex Clinical Studies
Rare Cancers: Special Considerations for Complex Clinical Studies
Date: Tuesday, November 17, 2020
Time: 11am EST(NA) / 4pm GMT (UK) / 5pm CEST (EU-Central)
Length: 60 minutes
All clinical trials face challenges, but for rare disease trials, there are additional and unique challenges. Recruiting patients with the accurate rare disease diagnosis is a significant hurdle, followed by the challenges of addressing the difficulty and strain of these diseases on the patients themselves throughout the course of the study. With many rare diseases being genetic in nature, outcomes and decisions weigh heavily on the patient families.
For rare oncology trials, it becomes even more complex, from recruiting patients with specific biomarkers and genetic characteristics to navigating complex logistics and timing with individualized therapies and addressing evolving trial designs. A high number of study sites are required to enroll a very small number of patients. Statistical significance may be limited as well, so analysis may hinge on individual patients and historical comparison. Additionally, working with regulatory authorities throughout the process is critical.
Join Deb Kientop, Vice President, Strategic Development, Oncology, Dr. Marie Bonneterre, Vice President, Medical Affairs, Oncology and Rachael Young, Director, Feasibility, on Tuesday, November 17 at 11:00 a.m. EST as they tackle these challenges in our webinar, Rare Cancers: Special Considerations for Complex Clinical Studies.
Speakers:
- Deb Kientop, Vice President, Strategic Development, Oncology, Synteract
- Dr. Marie Bonneterre, Vice President, Medical Affairs, Oncology, Synteract
- Rachael Young, Director, Feasibility, Synteract
